Stockwatch: Fanning The Embers Of M&A
Executive Summary
A drug approval at Sarepta, two acquisitions by Allergan and $15bn worth of dry powder at Takeda has prompted “biotech off to the races” commentaries by analysts and the press. This froth will probably dissipate.